236 related articles for article (PubMed ID: 24463616)
21. Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome.
Shayeganmehr D; Ramezannia F; Gharib B; Rezaeilaal A; Shahi F; Jafariazar Z; Afshar M
Naunyn Schmiedebergs Arch Pharmacol; 2023 Jul; 396(7):1571-1581. PubMed ID: 36418469
[TBL] [Abstract][Full Text] [Related]
22. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
Templeton AJ; Ribi K; Surber C; Sun H; Hsu Schmitz SF; Beyeler M; Dietrich D; Borner M; Winkler A; Müller A; von Rohr L; Winterhalder RC; Rochlitz C; von Moos R; Zaman K; Thürlimann BJ; Ruhstaller T;
Breast; 2014 Jun; 23(3):244-9. PubMed ID: 24656636
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
[TBL] [Abstract][Full Text] [Related]
24. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
[TBL] [Abstract][Full Text] [Related]
25. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Elyasi S; Shojaee FSR; Allahyari A; Karimi G
Phytother Res; 2017 Sep; 31(9):1323-1329. PubMed ID: 28635153
[TBL] [Abstract][Full Text] [Related]
26. Topical non-occlusive polymers in hand-foot syndrome.
Fabbrocini G; Cristaudo A; Ionescu MA; Panariello L; Robert G; Pellicano M; Ayala F
G Ital Dermatol Venereol; 2018 Apr; 153(2):165-171. PubMed ID: 29564873
[TBL] [Abstract][Full Text] [Related]
27. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Zhang RX; Wu XJ; Lu SX; Pan ZZ; Wan DS; Chen G
J Cancer Res Clin Oncol; 2011 Jun; 137(6):953-7. PubMed ID: 21113620
[TBL] [Abstract][Full Text] [Related]
28. [Effective Prevention of Hand-Foot Syndrome by the Consumption of Dried Bonito Broth].
Kamimura K; Shinagawa Y; Ogawa K; Kobayashi Y; Abe H; Yokoo T; Kamimura H; Kawai H; Suda T; Yamagiwa S; Baba H; Terai S
Gan To Kagaku Ryoho; 2016 Apr; 43(4):463-5. PubMed ID: 27220795
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib-associated hand-foot syndrome in Japanese patients.
Iijima M; Fukino K; Adachi M; Tsukamoto T; Murai M; Naito S; Minami H; Furuse J; Akaza H
J Dermatol; 2011 Mar; 38(3):261-6. PubMed ID: 21342228
[TBL] [Abstract][Full Text] [Related]
30. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
[TBL] [Abstract][Full Text] [Related]
31. Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
Ostwal V; Kapoor A; Mandavkar S; Chavan N; Gupta T; Mirani J; Saklani A; Desouza A; Murugan K; Nashikkar C; Gupta S; Ramaswamy A
Oncologist; 2020 Dec; 25(12):e1886-e1892. PubMed ID: 32717127
[TBL] [Abstract][Full Text] [Related]
32. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
Scontre VA; Martins JC; de Melo Sette CV; Mutti H; Cubero D; Fonseca F; Del Giglio A
J Diet Suppl; 2018 Sep; 15(5):606-612. PubMed ID: 29095653
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis.
Huang J; Ye S; Feng S; Zheng M; Zhong M
Int J Colorectal Dis; 2023 Mar; 38(1):61. PubMed ID: 36872385
[TBL] [Abstract][Full Text] [Related]
34. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
[TBL] [Abstract][Full Text] [Related]
35. Management of hand-foot syndrome induced by capecitabine.
Gressett SM; Stanford BL; Hardwicke F
J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy.
Braik T; Yim B; Evans AT; Kassem M; Mullane M; Lad T; Hussein L; Cleveland B; McDunn S
J Community Support Oncol; 2014 Feb; 12(2):65-70. PubMed ID: 24971407
[TBL] [Abstract][Full Text] [Related]
37. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
38. Herbal medicine for hand-foot syndrome induced by fluoropyrimidines: A systematic review and meta-analysis.
Deng B; Sun W
Phytother Res; 2018 Jul; 32(7):1211-1228. PubMed ID: 29682836
[TBL] [Abstract][Full Text] [Related]
39. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study.
Bozkurt Duman B; Kara B; Oguz Kara I; Demiryurek H; Aksungur E
J BUON; 2011; 16(4):759-64. PubMed ID: 22331734
[TBL] [Abstract][Full Text] [Related]
40. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
